Search company, investor...

Kringle Pharma

Founded Year




Total Raised


Date of IPO


Market Cap


About Kringle Pharma

Kringle Pharma is a clinical-stage biopharmaceutical company that engages in the research, development, and commercialization of HGF protein medicines for patients suffering from incurable diseases, acute spinal cord injuries, ALS, acute kidney injuries, and more.

Headquarters Location

207 Saito Bio Incubator 7-7-15 Saitoasagi, Ibaraki

Osaka, 567-0085,


Missing: Kringle Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kringle Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Kringle Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kringle Pharma is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Kringle Pharma Patents

Kringle Pharma has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Neurological disorders
  • Proteins
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Neurological disorders, Rare diseases, Proteins, Clusters of differentiation


Application Date


Grant Date



Related Topics

Transcription factors, Neurological disorders, Rare diseases, Proteins, Clusters of differentiation



Latest Kringle Pharma News

Kringle Pharma’s phase II ALS study falls short

Aug 16, 2022

Aug. 16, 2022 Kringle Pharma Inc. ’s phase II trial evaluating its recombinant human hepatocyte growth factor (HGF) ligand, oremepermin alfa , failed to meet both primary and secondary endpoints in a study of its potential to help people with amyotrophic lateral sclerosis (ALS). ALS is an intractable neurodegenerative disease that gradually impairs motor function due to degeneration of motor neurons. In Japan, roughly 10,000 patients have ALS. The most common symptom is muscle atrophy caused by motor neuron damage and loss, and therefore protection of motor neurons is considered beneficial for therapeutic efficacy. Kringle’s randomized, double-blind, placebo-controlled trial evaluated the candidate, administered intrathecally once every two weeks, on the primary endpoint of change in ALS Functional Rating Scale-Revised (ALSFRS-R) score at end of the 24-week treatment period. Osaka, Japan-based Kringle said there was a slowing of disease progression observed in the treatment group in some cases and it will conduct further analysis to interpret the results. The trial enrolled 46 ALS patients with Japan ALS Severity Classification of Grade 1 or 2, within 30 months of onset of the disease. The drug, also known as KP-100IT, was administered to 32 patients and 14 patients received placebo. There was no statistically significant difference between the KP-100IT group and the placebo group, and no statistically significant differences were observed in key secondary endpoints between the two groups, the company said. The ALS Severity Classification is classified from Grade 1 (least severe) to Grade 5 (most severe) defined by Japan’s Ministry of Health, Labor and Welfare (MHLW) Specific Disease Research Group. The ALSFRS-R measures 12 aspects of physical functions from patients’ daily lives. Each function is scored from 4 (normal) to 0 (no ability), with a total maximum score of 48 to a minimum score of 0. The ALS study began in May 2016 as an investigator-initiated study led by Masashi Aoki at the Tohoku University School of Medicine. Kringle said it would consult with Tohoku University to discuss further development after the data are analyzed. The incidence of adverse events was similar between the treatment group and placebo group, confirming that the intrathecal administration of KP-100IT was well-tolerated. Exploring the potential of HGF HGF was initially discovered as a growth factor in hepatocytes. Growth factors transmit signals to cells by binding to receptors on the surface of the cell and switching on cell proliferation. Research has shown that HGF has biological activity other than cell proliferation, and target cells are effective not only on hepatocytes but also on nervous system cells such as neurons and glial cells. Kringle’s platform is based on recombinant human HGF proteins, and clinical trials are being conducted across numerous indications. The company is running a phase III trial in acute spinal cord injury. The open label study is designed to enroll 25 participants aged 18 to 89 years who have suffered a cervical spinal cord injury within the past 78 hours to receive intrathecal administration of KP-100IT. Early treatment suppresses damage due to inflammatory reactions that occur immediately after injury, and HGF appears to suppress the secondary damage that occurs in the acute stage of spinal cord injury. Trial results are expected in late 2022. Data from a phase I/II trial disclosed in March 2019 also found KP-100IT to be safe and well-tolerated. But, on the primary endpoint of change of ASIA motor score at week 24 from baseline, it did not deliver significant improvement compared to placebo. The secondary endpoint in the study was determined by the change of ASIA motor score over time that showed difference compared to placebo in lower limb motor score at week 20 and 24. The percentage of patients who were classified as Frankel grade A at the beginning of the trial and improved to C1 at the end of observation were 26% (4/15) in KP-100IT and 6% (1/16) in placebo groups. In July, Kringle announced a research collaboration with Kyoto University to apply HGF research to regenerative medicine products. Kringle has been developing KP-100lT for rare diseases such as acute spinal cord injury, ALS, vocal fold scarring, and acute kidney injury. Kringle was previously developing HGF for skin ulcers, but the indication is no longer listed as under development, according to Cortellis. The compound received an orphan designation from Japan’s MHLW. In Tokyo, Kringle’s stock on the on the Tokyo Stock Exchange (TSE:4884) was down 15.3%, trading at ¥555 (US$4.17) per share at market close Aug. 15.

Kringle Pharma Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kringle Pharma Rank

Kringle Pharma Frequently Asked Questions (FAQ)

  • When was Kringle Pharma founded?

    Kringle Pharma was founded in 2001.

  • Where is Kringle Pharma's headquarters?

    Kringle Pharma's headquarters is located at 207 Saito Bio Incubator, Osaka.

  • What is Kringle Pharma's latest funding round?

    Kringle Pharma's latest funding round is IPO.

  • How much did Kringle Pharma raise?

    Kringle Pharma raised a total of $46.32M.

  • Who are the investors of Kringle Pharma?

    Investors of Kringle Pharma include Maruishi Pharmaceutical, Resona Capital, Yitu Capital, OKB Capital, Chishima Real Estate and 23 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.